Hepcidin predicts 5-year mortality after community-acquired pneumonia.

Kjersti OppenThor UelandAnnika Elisabet MichelsenPål AukrustTrude Steinsvik Øyvind Skadberg Cato BredeWilliam Ward SiljanEinar Husebye Jan Cato Holter Lars Heggelund

Published in: Infectious diseases (London, England) (2022)

In hospitalized patients with community-acquired pneumonia, low levels of hepcidin at admission predicted 5-year overall mortality, but not short-term adverse outcome.

Keyphrases

community acquired pneumonia
emergency department
iron deficiency
cardiovascular events
risk factors
adverse drug
type diabetes